In Brief: Abbott's Depacon
Executive Summary
Abbott's Depacon: Injectable formulation of valproate sodium is "approvable" as of June 6 for complex partial seizures and for simple and complex absence seizures. Related to Depakote (divalproex sodium) and Depakene (valproic acid), Depacon is also "approvable" as adjunct therapy for multiple seizure types. Abbott filed the Depacon NDA on March 20, 1995...